ClinicalTrials.gg

Program

Bortezomib

Also written as “bortezomib”, “VELCADE” and “VELCADE TM (bortezomib) for Injection”.

Its studies are mostly in Multiple Myeloma · Carcinoma, Non-Small-Cell Lung · Lymphoma, Mantle-Cell · Lymphoma, Follicular · Amyloidosis, led by 6 companies.

Furthest: phase 4, since Oct 15, 201462 company-led studies, 7 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson285 open or runningphase 4since Oct 15, 2014Sep 13, 2005Feb 14, 2029phase 3 · NCT04923893
Takeda250 open or runningphase 4since Nov 18, 2005Oct 28, 2002none ahead
Oncotherapeutics40 open or runningphase 2since Apr 24, 2006Apr 19, 2006none ahead
AbbVie32 open or runningphase 3since Nov 28, 2023Aug 19, 2016Dec 2027phase 3 · NCT06158841
AstraZeneca10 open or runningphase 4since Aug 23, 2023Aug 23, 2023none ahead
clinical-service-china10 open or runningphase 2since Mar 29, 2011Mar 29, 2011none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Jan 21, 2003.

  1. Oct 15, 2014Phase 4 study in Multiple MyelomaJohnson & Johnson · NCT02268890 · 18 enrolled · Taiwan
  2. May 26, 2016Phase 3 study in Multiple MyelomaJohnson & Johnson · NCT02811978 · 81 enrolled · China
  3. Aug 1, 2016Phase 2 study in Multiple MyelomaJohnson & Johnson · NCT02874742 · 224 enrolled · United States
  4. Aug 19, 2016AbbVie's first study: phase 2 study in Multiple MyelomaNew to AbbVieAbbVie · NCT02902965 · 74 enrolled · Czechia, Germany, Greece and more
  5. Oct 31, 2016Phase 2 study in Multiple MyelomaJohnson & Johnson · NCT02951819 · 101 enrolled · United States
  6. Oct 11, 2017Phase 2 study in Multiple MyelomaAbbVie · NCT03314181 · 156 enrolled · United States, Australia, Canada and more
  7. Nov 27, 2019Phase 3 study in Multiple MyelomaJohnson & Johnson · NCT04181827 · 419 enrolled · United States, Australia, Belgium and more
  8. Jun 10, 2021Phase 3 study in Multiple MyelomaJohnson & Johnson · NCT04923893 · 743 enrolled · United States, Argentina, Australia and more
  9. Oct 8, 2021Phase 3 study in Multiple MyelomaJohnson & Johnson · NCT05083169 · 587 enrolled · United States, Argentina, Belgium and more
  10. Sep 30, 2022Phase 2 study in Lymphoma, Mantle-CellJohnson & Johnson · NCT05564052 · 36 enrolled · Brazil, Czechia, Greece and more
  11. Oct 5, 2022Phase 3 study in Multiple MyelomaJohnson & Johnson · NCT05572515 · 614 enrolled · United States, Australia, Austria and more
  12. Aug 23, 2023AstraZeneca's first study: phase 4 study in HypophosphatasiaNew to AstraZenecaAstraZeneca · NCT06015750
  13. Nov 28, 2023Phase 3 study in Multiple MyelomaAbbVie · NCT06158841 · 421 enrolled · United States, Australia, Austria and more
  14. Aug 27, 2024Phase 2 study in Multiple MyelomaJohnson & Johnson · NCT06577025 · 43 enrolled · United States, Australia, Brazil and more

Ahead

  1. Dec 2027Primary completion: phase 3 study in Multiple MyelomaAbbVie · NCT06158841
  2. Feb 14, 2029Primary completion: phase 3 study in Multiple MyelomaJohnson & Johnson · NCT04923893
  3. Sep 2, 2030Primary completion: phase 2 study in Multiple MyelomaJohnson & Johnson · NCT06577025
  4. May 2031Primary completion: phase 2 study in Multiple MyelomaAbbVie · NCT03314181

TargetBeta

“26S proteasome inhibitor; 26S proteasome inhibitor”ChEMBL 37, by rule

Other programs on the same 38 targets

ProgramCompanyFurthest phaseStudies
carfilzomibruleAmgenphase 438

Studies

The newest 60 of 62 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT06577025Multiple Myeloma · United States, Australia, Brazil and more2Active, not recruitingJohnson & JohnsonSep 2, 203043
NCT06158841Multiple Myeloma · United States, Australia, Austria and more3Active, not recruitingAbbVieDec 2027421
NCT06015750Hypophosphatasia4WithdrawnAstraZenecaMar 13, 20300
NCT05572515Multiple Myeloma · United States, Australia, Austria and more3Active, not recruitingJohnson & JohnsonOct 13, 2025614
NCT05564052Lymphoma, Mantle-Cell · Brazil, Czechia, Greece and more2CompletedJohnson & JohnsonDec 6, 202336
NCT05083169Multiple Myeloma · United States, Argentina, Belgium and more3Active, not recruitingJohnson & JohnsonAug 1, 2025587
NCT04923893Multiple Myeloma · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonFeb 14, 2029743
NCT04181827Multiple Myeloma · United States, Australia, Belgium and more3Active, not recruitingJohnson & JohnsonMay 1, 2024419
NCT03314181Multiple Myeloma · United States, Australia, Canada and more2Active, not recruitingAbbVieMay 2031156
NCT02951819Multiple Myeloma · United States2CompletedJohnson & JohnsonMar 8, 2018101
NCT02902965Multiple Myeloma · Czechia, Germany, Greece and more2CompletedAbbVieOct 26, 201874
NCT02874742Multiple Myeloma · United States2CompletedJohnson & JohnsonJan 25, 2019224
NCT02811978Multiple Myeloma · China3CompletedJohnson & JohnsonMay 7, 201881
NCT02268890Multiple Myeloma · Taiwan4CompletedJohnson & JohnsonJul 201518
NCT01902862Lymphoma, Follicular · Germany2TerminatedJohnson & JohnsonAug 20077
NCT01801436Multiple Myeloma3CompletedJohnson & JohnsonApr 200814
NCT01910987Multiple Myeloma · Belgium, Finland, France and more3CompletedJohnson & JohnsonFeb 201680
NCT01695330Multiple Myeloma · United States2TerminatedOncotherapeuticsOct 20155
NCT01539083Multiple Myeloma · Australia, China, Korea, Republic of3CompletedJohnson & JohnsonDec 30, 2015256
NCT01328236Leukemia, Plasma Cell · China2UNKNOWNclinical-service-chinaSep 201320
NCT01286077Multiple Myeloma · Austria, Czech Republic, Denmark and more2CompletedJohnson & JohnsonNov 2012106
NCT01040871Lymphoma, Large B-Cell, Diffuse · Belgium2CompletedTakedaJun 2012164
NCT00985959Multiple Myeloma · Japan1CompletedJohnson & JohnsonJun 2010101
NCT00931918Acromesomelic dysplasia, Maroteaux type · United States2CompletedTakedaAug 2015206
NCT00908232Multiple Myeloma · France, Germany, Greece and more2CompletedJohnson & JohnsonAug 2011163
NCT00850499Lymphoma, Follicular · France, Germany, Greece and more2TerminatedTakedaSep 201112
NCT00833560Multiple Myeloma · Germany2CompletedJohnson & JohnsonJun 2009401
NCT00813150Multiple Myeloma · Germany3CompletedJohnson & JohnsonJan 201396
NCT00752518Multiple Myeloma2CompletedJohnson & Johnson35
NCT00742404Multiple Myeloma · United States2UNKNOWNOncotherapeuticsJul 201035
NCT00722137Lymphoma, Mantle-Cell · United States, Austria, Belgium and more3CompletedTakedaJan 1, 2014487
NCT00718640Multiple Myeloma · Canada2TerminatedJohnson & JohnsonDec 200910
NCT00715208Lymphoma, Follicular · United States, Puerto Rico2CompletedTakedaFeb 201155
NCT00706953Multiple Myeloma2WithdrawnJohnson & JohnsonJun 20100
NCT00610792Ovarian Neoplasms · Italy, Switzerland2WithdrawnTakedaSep 200991
NCT00608907Multiple Myeloma · Israel, Italy, Poland and more1CompletedTakedaMar 201061
NCT00561743Multiple Myeloma2CompletedJohnson & JohnsonMay 200750
NCT00531453Multiple Myeloma · Austria2CompletedTakedaApr 200998
NCT00441168Multiple Myeloma · Croatia, Germany, Hungary and more2TerminatedJohnson & JohnsonJan 200830
NCT00431769Multiple Myeloma · Austria, Belgium, France and more2CompletedJohnson & JohnsonFeb 2009130
NCT00416273Multiple Myeloma · Germany3CompletedJohnson & JohnsonMay 2013217
NCT00416208Multiple Myeloma · Germany3CompletedJohnson & JohnsonMay 2013154
NCT00343720Carcinoma, Non-Small-Cell Lung · Belgium2CompletedTakedaOct 2007
NCT00317811Multiple Myeloma · United States2CompletedOncotherapeuticsFeb 200935
NCT00316940Multiple Myeloma · United States1CompletedOncotherapeuticsJun 200836
NCT00312845Lymphoma, Non-Hodgkin · United States, Argentina, Australia and more3CompletedTakedaJun 2010676
NCT00298766Amyloidosis · United States2CompletedTakedaJul 200970
NCT00283634NSCLC · United States2TerminatedTakedaJul 2007
NCT00257114Multiple Myeloma · United States4CompletedTakedaMar 2007
NCT00216697Multiple Myeloma2CompletedJohnson & Johnson13
NCT00129207Neoplasms · United States1CompletedTakedaSep 2006
NCT00117351Carcinoma, Non-Small-Cell Lung · United States2TerminatedTakedaJun 2007
NCT00111319Multiple Myeloma · United States3CompletedTakedaJul 2007
NCT00085696Lymphoma, B-Cell · United States2CompletedTakedaApr 200666
NCT00080405Multiple Myeloma1CompletedTakedaJun 200540
NCT00064636Advanced Non-Small Cell Lung Cancer1TerminatedTakeda46
NCT00064610Prostatic Neoplasms · United States2CompletedTakedaDec 2004102
NCT00063726Multiple Myeloma · United States, Austria, Belgium and more3CompletedTakedaMay 2005600
NCT00063713Lymphoma, Mantle-Cell · United States2CompletedTakedaDec 2005152
NCT00051987Colorectal Neoplasms · United States2CompletedTakedaMar 2004175

How it is read

Names in the registry

  • “Bortezomib”, 42 entries
  • “bortezomib”, 18 entries
  • “VELCADE”, 6 entries
  • “VELCADE TM (bortezomib) for Injection”, 2 entries
  • “VELCADE TM (bortezomib) for Injection, or PS-341”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.